OverviewSuggest Edit

Spark Therapeutics is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.

TypePublic
Founded2013
HQPhiladelphia, PA, US
Websitesparktx.com
Employee Ratings4.1
Overall CultureA-

Latest Updates

Employees (est.) (Feb 2019)368(+17%)
Job Openings112
Revenue (FY, 2018)$64.7 M(+437%)
Share Price (Dec 2019)$113.6
Cybersecurity ratingAMore

Key People/Management at Spark Therapeutics

Jeffrey D. Marrazzo

Jeffrey D. Marrazzo

Chief Executive Officer, Co-Founder
Lars Ekman

Lars Ekman

Director
Katherine A. High

Katherine A. High

President and Head of Research and Development
Stephen Webster

Stephen Webster

Chief Financial Officer
Daniel R. Faga

Daniel R. Faga

Chief Business Officer
Anand Mehra

Anand Mehra

Director
Show more

Spark Therapeutics Office Locations

Spark Therapeutics has an office in Philadelphia
Philadelphia, PA, US (HQ)
3737 Market St
Show all (1)

Spark Therapeutics Financials and Metrics

Spark Therapeutics Revenue

Spark Therapeutics's revenue was reported to be $64.73 m in FY, 2018
USD

Revenue (Q3, 2019)

22.4m

Net income (Q3, 2019)

(66.6m)

EBIT (Q3, 2019)

(68.7m)

Market capitalization (17-Dec-2019)

4.4b

Closing stock price (17-Dec-2019)

113.6

Cash (30-Sept-2019)

207.1m

EV

4.2b
Spark Therapeutics's current market capitalization is $4.4 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

633.9k22.1m20.2m12.1m64.7m

Revenue growth, %

3380%(9%)

General and administrative expense

7.9m23.4m48.1m111.1m124.9m

R&D expense

16.4m46.0m86.4m135.2m125.3m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

2.3m1.3m1.3m1.3m1.3m1.3m1.3m1.5m1.9m15.7m25.2m10.7m20.8m13.5m22.4m

Cost of goods sold

121.0k269.0k318.0k

Gross profit

15.6m24.9m10.4m

Gross profit Margin, %

99%99%97%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

74.6m293.5m58.9m96.7m95.2m

Accounts Receivable

244.4k16.9m16.8m7.9m47.4m

Prepaid Expenses

40.5m

Inventories

25.6m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

234.4m223.0m212.2m275.0m225.0m90.6m27.5m36.8m146.4m127.7m201.1m161.6m76.3m124.1m207.1m

Accounts Receivable

669.4k933.1k1.3m812.8k1.2m1.0m5.9m5.0m6.0m21.2m25.2m13.5m20.5m59.9m35.5m

Prepaid Expenses

3.7m5.5m4.4m6.7m6.4m10.5m

Inventories

5.6m12.7m20.7m30.1m30.9m31.9m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(24.3m)(47.1m)(123.7m)(253.5m)(78.8m)

Depreciation and Amortization

169.8k1.7m3.6m4.9m

Inventories

(25.6m)

Accounts Payable

2.3m9.1m10.0m13.0m8.7m
Quarterly
USDFY, 2014

Financial Leverage

1.6 x
Show all financial metrics

Spark Therapeutics Operating Metrics

FY, 2016

Patents and Patent Applications

297
Show all operating metrics

Spark Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Spark Therapeutics Online and Social Media Presence

Embed Graph

Spark Therapeutics Company Culture

  • Overall Culture

    A-

    87/100

  • CEO Rating

    A+

    90/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Spark Therapeutics News and Updates

NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease

STATE COLLEGE, Pa. and PHILADELPHIA, Sept. 7, 2021 /PRNewswire/ -- NeuExcell Therapeutics and Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced a gene therapy collaboration aimed at developing a safe and effective treatment for patients suffering...

Senti Bio Enters Collaboration with Spark Therapeutics to Develop Next-Generation Precision Gene Therapies

- Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies targeting the central nervous system, eye or liver -

Spark Therapeutics Enters Collaboration with Senti Bio to Bolster Industry-Leading Gene Therapy Research Platform

Collaboration combines Senti Bio’s leading-edge gene circuit technology platform and high-throughput synthetic promoter design capabilities with Spark Therapeutics’ investigational gene therapies targeting the central nervous system, eye or liver

Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer

PHILADELPHIA, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Cynthia Pussinen as…

Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease

First participant dosed in the RESOLUTESM trial, a Phase 1/2 dose-escalation study of SPK-3006

Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy Officer

PHILADELPHIA, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Michael Retterath a…
Show more

Spark Therapeutics Blogs

Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights

Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights Content Import Tue, 10/30/2018 - 07:32 Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Resu…

Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases

Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases Content Import Thu, 10/25/2018 - 07:34 Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for…

Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate

Data from IND-enabling studies in three species support moving SPK-3006 into the clinic in 2019 PHILADELPHIA , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today

Spark Therapeutics Frequently Asked Questions

  • When was Spark Therapeutics founded?

    Spark Therapeutics was founded in 2013.

  • Who are Spark Therapeutics key executives?

    Spark Therapeutics's key executives are Jeffrey D. Marrazzo, Lars Ekman and Katherine A. High.

  • How many employees does Spark Therapeutics have?

    Spark Therapeutics has 368 employees.

  • What is Spark Therapeutics revenue?

    Latest Spark Therapeutics annual revenue is $64.7 m.

  • What is Spark Therapeutics revenue per employee?

    Latest Spark Therapeutics revenue per employee is $175.9 k.

  • Who are Spark Therapeutics competitors?

    Competitors of Spark Therapeutics include Human Stem Cells Institute, Dr Lal PathLabs and Sanesco.

  • Where is Spark Therapeutics headquarters?

    Spark Therapeutics headquarters is located at 3737 Market St, Philadelphia.

  • Where are Spark Therapeutics offices?

    Spark Therapeutics has an office in Philadelphia.

  • How many offices does Spark Therapeutics have?

    Spark Therapeutics has 1 office.